By reducing the viral load in HIV-infected individuals to undetectable levels, Tenofovir significantly lowers the risk of transmitting the virus to others. This has profound implications for the control of HIV at both the individual and population levels. Studies have shown that individuals adhering to HAART, including TDF, have a near-zero risk of transmitting HIV to their sexual partners, a concept known as Treatment as Prevention (TasP).
